Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 897-900, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tadepalli, S. M.
Right arrow Articles by Quinn, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tadepalli, S. M.
Right arrow Articles by Quinn, R. P.

Clinical Chemistry, Vol 36, 897-900, Copyright © 1990 by American Association for Clinical Chemistry

Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit

SM Tadepalli, L Puckett, S Jeal, L Kanics and RP Quinn
Experimental Therapy Division, Burroughs Wellcome Co., Research Triangle Park, NC 27709.

We developed an ancillary procedure for the ZDV-Trac RIA (Incstar) to allow simultaneous determination of both zidovudine (3'-azido-3'- deoxythymidine, ZDV, AZT, Retrovir) and its metabolite, the glucuronide of ZDV (3'-azido-3'-deoxy-5'-O-beta-D-glucopyranuronosylthymidine, ZDVG, GAZT), in human serum and urine. Using the ZDV-Trac RIA, we measured ZDV concentrations before and after ZDVG in samples was hydrolyzed to ZDV by beta-glucuronidase (EC 3.2.1.31); ZDVG concentration was calculated as the difference between the two results. This method enables rapid evaluation of a large number of samples with a total turn-around time of 6 h. The lower detection limit of the RIA was 0.27 micrograms/L; the measurements varied linearly with ZDV concentrations from 0.27 to 217 micrograms/L, with the 50% inhibitory concentration being approximately 10 micrograms/L. Analytical recoveries of inhouse serum and urine controls for both ZDV and ZDVG exceeded 90%. Coefficients of variation (CVs) of serum controls were less than 6% for ZDV and less than 11% for ZDVG; for urine controls, CVs for both ZDV and ZDVG were less than 6%. Results for ZDVG concentrations obtained by HPLC and by the ZDV-Trac RIA system compared well: r = 0.978, slope 1.0, for serum samples, and r = 0.993, slope 1.09, for urine samples.


The following articles in journals at HighWire Press have cited this article:


Home page
 Antimicrob. Agents Chemother.Home page
J. A. McDowell, Y. Lou, W. S. Symonds, and D. S. Stein
Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults
Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2061 - 2067.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
L. H. Wang, G. E. Chittick, and J. A. McDowell
Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection
Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1708 - 1715.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
J. V. Mei, W. H. Hannon, T. L. Dobbs, C. J. Bell, C. Spruill, and M. Gwinn
Radioimmunoassay for monitoring zidovudine in dried blood spot specimens
Clin. Chem., February 1, 1998; 44(2): 281 - 286.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.